$SEEL News
Last published 2y ago
- 2y agoSEELSeelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter MarketPR NewswireSeelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
- 2y agoSEELSeelos Announces Postponement of its Annual Meeting of StockholdersPR NewswireSeelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central...
- 2y agoSEELSeelos Therapeutics Announces 1-for-16 Reverse Stock SplitPR NewswireSeelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
- 2y agoSEELSeelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSDPR NewswireSeelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central...
- 2y agoSEELSeelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesPR NewswireSeelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
- 2y agoSEELSeelos Therapeutics Announces 1-for-8 Reverse Stock SplitPR NewswireSeelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
- 2y agoSEELSeelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and CollaborationsPR NewswireSeelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central...
- 2y agoSEELSeelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)PR NewswireSeelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central...
- 2y agoSEELSeelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesPR NewswireSeelos Therapeutics, Inc. (Nasdaq: SEEL) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for...
- 2y agoCYBNCMPSMNMDSEEL+1How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) ConditionPR NewswireThe coming years could see a massive shift in the U.S. government's approach to regulating hallucinogenic drugs. Several biopharma companies are...
- 2y agoSEELSeelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002PR NewswireSeelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central...
- 2y agoSEELLeading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024PR NewswireSeelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central...
- 2y agoSEELSeelos Therapeutics, Inc. Releases Letter to its StockholdersPR NewswireSeelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central...
- 2y agoSEELSeelos Therapeutics Announces Closing of Public OfferingPR NewswireSeelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central...
- 2y agoSEELSeelos Therapeutics Announces Pricing of $5.55 Million Public OfferingPR NewswireSeelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central...
- 2y agoSEELSeelos Therapeutics Announces Proposed Public OfferingPR NewswireSeelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central...
- 2y agoSEELSeelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder (PTSD)PR NewswireSeelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central...
- 2y agoSEELSeelos Therapeutics Announces 1-for-30 Reverse Stock SplitPR NewswireSeelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
- 3y agoSEELSeelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023PR NewswireSeelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central...
- 3y agoSEELSeelos Therapeutics Retains Canaccord Genuity in Connection with Review of Potential Partnerships and CollaborationsPR NewswireSeelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central...
- 3y agoSEELSeelos Therapeutics Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's DiseasePR Newswire- Treatment with SLS-005 demonstrated a 46% reduction in tau protein and an 18% reduction in NfL biomarker from baseline values within six months - Seelos has been selected to present these data at Neuroscience 2023 to
- 3y agoSEELSeelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common StockPR NewswireNEW YORK, Sept. 21, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS)
- 3y agoSEELSeelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of SuicidePR NewswireSLS-002 demonstrated early and persistent clinically meaningful reductions in symptoms of depression and acute suicidality Robust Response and Remission Rates were observed using the Montgomery-Åsberg Depression Rating
- 3y agoSEELSeelos Therapeutics Provides Second Quarter 2023 Clinical UpdatePR Newswire- Seelos expects to release top-line data in its registration directed study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in adults with Major Depressive Disorder (MDD) in the
- 3y agoSEELSeelos Therapeutics Announces the Close of Enrollment of its Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in Adults with Major Depressive Disorder (MDD)PR Newswire- There is currently no FDA approved treatment for ASIB in MDD. - Top-line data from this study is expected in the third quarter of 2023. NEW YORK, June 22, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL)
- 3y agoSEELSeelos Therapeutics to Participate in Two Upcoming Healthcare ConferencesPR NewswireNEW YORK, May 22, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders
- 3y agoSEELSeelos Therapeutics Provides Clinical Update and Reports First Quarter 2023 Financial ResultsPR Newswire- Seelos expects to release top-line data in two registrational studies in 2023 NEW YORK, May 15, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL) ("Seelos"), a clinical-stage biopharmaceutical
- 3y agoSEELSeelos Therapeutics to Present a Poster on SLS-009 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual MeetingPR Newswire- SLS-009 is Seelos' First Internally Created Program - Seelos is also evaluating SLS-009 in two preclinical in vivo studies in Amyotrophic Lateral Sclerosis and Alzheimer's Disease NEW YORK, May 5, 2023
- 3y agoSEELSeelos Therapeutics Doses the First Amyotrophic Lateral Sclerosis (ALS) Patient with SLS-005 in an Expanded Access ProgramPR Newswire- The Expanded Access Program is funded by a grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Accelerating Access to Critical Therapies for ALS (ACT for ALS) for ALS patients who
- 3y agoSEELSeelos Therapeutics Announces Business Update on its Key ProgramsPR NewswireNEW YORK, March 29, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders
- 3y agoSEELSeelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common StockPR NewswireNEW YORK, March 10, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS)
- 3y agoSEELSeelos Therapeutics to Participate in 43rd Annual Cowen Health Care ConferencePR NewswireNEW YORK, Feb. 15, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases,
- 3y agoSEELSeelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS PlatformPR Newswire- The randomized, double-blind, placebo-controlled study is evaluating SLS-005 in 160 patients over 24 weeks and Seelos anticipates delivering topline data in the second half of 2023. - Seelos will also enroll patients
- 3y agoSEELSeelos Therapeutics to Present a Poster on SLS-004 at the 11th Annual Alzheimer's & Parkinson's Drug Development SummitPR Newswire- Seelos recently released in vivo gene therapy data of SLS-004 utilizing CRISPR-dCas9 in Parkinson's disease demonstrating downregulation of alpha synuclein and recovery of tyrosine hydroxylase-positive (TH+)
- 3y agoSEELSeelos Therapeutics Doses First Patients in an Ethnobridging Study with SLS-002 (Intranasal Racemic Ketamine)PR Newswire-Seelos is conducting a Phase I ethnobridging study in healthy Japanese and non-Asian subjects to evaluate the safety and pharmacokinetic profiles of SLS-002. NEW YORK, Feb. 6, 2023 /PRNewswire/ -- Seelos Therapeutics,
- 3y agoSEELSeelos Therapeutics to Participate in the 12th Annual LifeSci Partners Corporate Access EventPR NewswireNEW YORK, Dec. 22, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases,
- 3y agoSEELSeelos Therapeutics Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's DiseasePR Newswire-A single dose of SLS-004 produced a substantial increase in recovery of tyrosine hydroxylase-positive (TH+) dopaminergic neurons that are known to degenerate in patients with Parkinson's disease -Degeneration of TH+
- 3y agoSEELSeelos Therapeutics Releases the Itinerary for its Research and Development Update Conference Call and Webcast to be Held on December 15, 2022PR NewswireNEW YORK, Dec. 8, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases,
- 3y agoSEELSeelos Therapeutics to Hold a Research and Development Update Conference Call and Webcast on December 15, 2022PR NewswireNEW YORK, Nov. 23, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases,
- 4y agoSEELSeelos Therapeutics to Participate in the Guggenheim 4th Annual Immunology and Neurology DayPR NewswireNEW YORK, Nov. 7, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases,
- 4y agoSEELSeelos Therapeutics Doses First Patient in a Registrational Phase II/III study of SLS-005 in Spinocerebellar AtaxiaPR NewswireSeelos will also present at the International Congress for Ataxia Research in November NEW YORK, Oct. 25, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused
- 4y agoATAIOPTHFSEELTAK+1Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer's DiseasePR NewswireFN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Oct. 5, 2022 /PRNewswire/ -- A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer's disease, announcing recently that it has gotten approval from A
- 4y agoSEELSeelos Therapeutics to Collaborate with the Healey & AMG Center for ALS in an Expanded Access Program Funded by a Grant from the National Institute of Neurological Disorders and Stroke under the Accelerating Access to Critical Therapies for ALS Act (ACT for ALS)PR Newswire- ACT for ALS Funding is for an Expanded Access Program to Study SLS-005 in Amyotrophic Lateral Sclerosis Patients Who Do Not Qualify for Clinical Trials NEW YORK, Sept. 30, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stag
- 4y agoACHCSEELSelect Acadia Healthcare Hospitals to Participate in Clinical Trial for Acute Suicidal Ideation and Behavior in Major Depression DrugBusiness WireProgram aligns with Acadia's mission to provide safe, innovative care to patients in great need Acadia Healthcare Company, Inc. (NASDAQ:ACHC) today announced that select facilities from its network of acute care behavioral health hospitals will parti
- 4y agoACHCSEELSeelos Therapeutics Announces the Participation of Acadia Healthcare in the Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive DisorderPR Newswire- Acadia Healthcare is the Largest Stand-Alone Behavioral Health Company in the United States Operating a Network of Nearly 240 Behavioral Health Facilities in 39 States and Puerto Rico NEW YORK, Sept. 13, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc.
- 4y agoSEELSeelos Therapeutics to Participate in the Guggenheim Nantucket Therapeutics ConferencePR NewswireNEW YORK, Sept. 9, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will parti
- 4y agoATAINUMIFOPTHFSEEL+1Psychedelics Use Among Young Adults Reaches All-Time HighPR NewswireFN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Sept. 1, 2022 /PRNewswire/ -- Young adults are using more hallucinogens than ever. According to a National Institute of Health survey, the amount of people between age 19 to 30 who
- 4y agoSEELSeelos Therapeutics to Participate in Two Upcoming Psychedelic ConferencesPR Newswire- Seelos' SLS-002 is currently being developed specifically to treat the symptoms of suicidality associated with major depression NEW YORK, Aug. 30, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical compan
- 4y agoSEELSeelos Therapeutics Receives a Research and Development Grant from The Michael J. Fox Foundation for Parkinson's Research for SLS-004PR NewswireSLS-004 Utilizes CRISPR-dCas9 to Target the SNCA Gene Responsible for the Expression of Alpha-Synuclein NEW YORK, Aug. 24, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the develop
- 4y agoSEELSeelos Therapeutics Doses First Patient in an Open Label Basket Study of SLS-005 in Amyotrophic Lateral Sclerosis in Australia and Provides an Enrollment Update of its Study on the HEALEY ALS PlatformPR NewswireSLS-005 Study on the HEALEY ALS Platform is Expected to Complete Enrollment this Quarter; Top-Line Data Readout Expected Mid-2023 NEW YORK, July 18, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical compan